A Study About the Operation Efficacy and the Early Stage Safety of Heavy Ion Beam Treatment System in Solid Tumor

NCT ID: NCT05764486

Last Updated: 2023-03-10

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 6 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-06-21
• Study Completion Date: 2022-12-20

Brief Summary

The main purpose of this study is to investigate the safety of Hitachi's Heavy Ion Beam Therapy System HyBEAT for treating patients with solid tumor in Taipei Veterans General Hospital, including patients early-stage adverse reactions and the efficacy on tumors, as well as to assess the operation efficacy of the device.

Conditions

Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

treatment plan

Treatment plan performed by Hitachi's Heavy Ion Beam Therapy System HyBEAT will be designed to suit the particular needs of each subject and the course of treatment will differ for each subject depending on the type of tumor, varying from 1 day to 4 weeks. All subjects will be monitored for 12 weeks after receiving the last treatment.

Group Type: OTHER

Hitachi's Heavy Ion Beam Therapy System HyBEAT

Intervention Type: DEVICE

treating patients with solid tumor

Interventions

Hitachi's Heavy Ion Beam Therapy System HyBEAT

treating patients with solid tumor

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Must be 20 years of age inclusive, male or female

2. Diagnosed with one of the following cancer: head and neck cancer, lung cancer, liver cancer, prostate cancer, osteosarcoma or bone and soft-tissue tumours

3. Having a lesion of less than 12cm

4. Having no metastasis at distant organ sites

5. Having a life expectancy of more than 12 weeks or longer

6. ECOG Performance Status (ECOG PS): 0, 1 or 2

7. Maintain the function of major organs and satisfy the following criteria: WBC≥3,000 / mm3 , Plt

≥75,000 / mm3 (assuming no serious bleeding tendency below 100,000), Hb≥9.5 g / dl

8. Able to maintain body position during irradiation

9. Based on his/her free will, agree to participate in the clinical study and sign and date the informed consent form after understanding the clinical study.

Exclusion Criteria

1. Weigh more than or equal to 135kg

2. Subjects need chemotherapy or immunotherapy as concomitant treatment

3. Have received radiotherapy on the area planned to be irradiated

4. Have received local treatment that might potentially affect endpoint evaluation, 4 weeks prior to the screening process (for instance TACE etc.)

5. Have been treated with targeted therapy, chemotherapy or immunotherapy 4 weeks prior to the screening process

6. Participated in other clinical studies within 12 weeks before screening (studies using questionnaire are exemption)

7. Subjects contraindicated in using radiotherapy

8. Wearing electronic devices, for example implantable cardiac pacemakers, implantable defibrillators, cerebrospinal stimulators, artificial hearts and cochlear implants, where the function and activity may be affected by radiation

9. Have been diagnosed with another active, uncontrolled cancer

10. Subjects whose irradiated area has active or persistent infectious disease

11. Has autoimmune diseases or connective tissue diseases

12. Subjects with other serious complications

13. Pregnant or currently breastfeeding

14. Planning to give birth or unable to take contraception during the screening and treatment period, as well as within 52 weeks after receiving the last treatment, regardless of gender.

15. Subjects who are judged by the investigators as unsuitable

• Minimum Eligible Age: 20 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Taipei Veterans General Hospital, Taiwan

OTHER_GOV

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Keng-Li, Lan

Role: PRINCIPAL_INVESTIGATOR

Doctor

Locations

Cancer Center, Taipei Veterans General Hospital

Taipei, , Taiwan

Countries

Taiwan

Other Identifiers

2021-02-013C

Identifier Type: -

Identifier Source: org_study_id